Advertisement

Journal of General Internal Medicine

, Volume 34, Issue 2, pp 281–284 | Cite as

Rising Mortality Rate of Cervical Cancer in Younger Women in Urban China

  • Min Wei
  • Wei Zhou
  • Yongyi Bi
  • Hong Wang
  • Yu Liu
  • Zhi-Jiang ZhangEmail author
Original Research

Abstract

Background

In recent decades, much effort has been made in China to reduce the burden of cervical cancer.

Objective

Our study’s purpose was to examine trends of cervical cancer mortality in each 5-year age group for urban and rural Chinese women, respectively.

Designs

Retrospective analysis of cervical cancer mortality from 1987 to 2015 from the World Health Organization Cancer Mortality Database and China Health Statistical Yearbooks.

Participants

Chinese women.

Main Measures

Trends were examined using annual percent change (APC) and average annual percent change (AAPC) via Joinpoint regression models for each 5-year age group in urban and rural areas, respectively.

Results

In urban China, mortality rate of cervical cancer increased significantly among urban women aged 25–54 years (AAPC 2.12~5.49%), in contrast to a decline trend among urban women older than 60 years (AAPC − 3.61~− 5.35%). In rural China, cervical cancer rates declined in all age groups, but the magnitude was smaller in women aged 30–54 years (AAPC − 0.59~− 2.20%) compared to women older than 55 years (AAPC − 3.06~− 4.33%).

Conclusion

Mortality rate of cervical cancer is rising at an alarming rate in younger women in urban China. Timely intervention is required for these vulnerable populations.

KEY WORDS

cervical cancer disparity age-specific mortality trend 

Notes

Authors’ Contributions

Min Wei drafted the manuscript; Wei Zhou drafted the manuscript and collected and analyzed data; Yongyi Bi, Hong Wang, and Yu Liu edited and commented the manuscript; and Zhi-Jiang Zhang concepted the study, supervise the research, and edited the manuscript.

Funding

The work was financially supported by the National Natural Science Foundation of China (grant number 81641123) and the Fundamental Research Funds for the Central Universities (grant number 2042017kf0193).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Supplementary material

11606_2018_4732_MOESM1_ESM.docx (18 kb)
ESM 1 (DOCX 17 kb)

References

  1. 1.
    Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomark Prev 2017; 26: 444–457.CrossRefGoogle Scholar
  2. 2.
    Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol 2017; 18(12): 1579–1589.Google Scholar
  3. 3.
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.CrossRefGoogle Scholar
  4. 4.
    Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929–936.CrossRefGoogle Scholar
  5. 5.
    Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010; 11: 1160–1171.CrossRefGoogle Scholar
  6. 6.
    Pan QJ, Hu SY, Zhang X, et al. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Cancer Cytopathol 2013; 121: 473–482.CrossRefGoogle Scholar
  7. 7.
    Dong L, Wang MZ, Zhao XL, et al. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. Gynecol Oncol 2018; 148(1): 103–110.Google Scholar
  8. 8.
    Zheng B, Yang H, Li Z, et al. HPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China. J Cancer 2017; 8: 2436–2441.CrossRefGoogle Scholar
  9. 9.
    Lv XL, Hou M, Duan XJ. Correlation analysis between the parameters of contrast-enhanced ultrasonography in evaluating cervical cancer metastasis and expression of E-cadherin. Oncol Lett 2017; 14: 4641–4646.CrossRefGoogle Scholar
  10. 10.
    Wei L, Gan Q, Ji T. Cervical cancer histology image identification method based on texture and lesion area features. Comput Assist Surg (Abingdon) 2017; 22: 186–199.CrossRefGoogle Scholar
  11. 11.
    Li X, Wang L, Li Y, Song P. The Value of Diffusion-Weighted Imaging in Combination With Conventional Magnetic Resonance Imaging for Improving Tumor Detection for Early Cervical Carcinoma Treated With Fertility-Sparing Surgery. Int J Gynecol Cancer 2017; 27: 1761–1768.CrossRefGoogle Scholar
  12. 12.
    Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 707–710.CrossRefGoogle Scholar
  13. 13.
    Wu SG, Zhang WW, Sun JY, Li FY, He ZY, Zhou J. Multimodal treatment including hysterectomy improves survival in patients with locally advanced cervical cancer: A population-based, propensity score-matched analysis. Int J Surg 2017; 48: 122–127.CrossRefGoogle Scholar
  14. 14.
    Qi YX, Liu K, Yin J, Li L. Evaluation of short- and long-term efficacy of chemoradiotherapy for advanced cervical cancer using HSP70 protein combined with multimodal MRI. J Cell Biochem 2018; 119(4): 3017–3029.Google Scholar
  15. 15.
    Lei H, Gui D, He Y. Short- and long-term outcomes of laparoscopic radical hysterectomy for obese patients with cervical cancer. J BUON 2017; 22: 958–965.Google Scholar
  16. 16.
    Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol 2014; 180: 11–14.CrossRefGoogle Scholar
  17. 17.
    Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34: 2323–2328.CrossRefGoogle Scholar
  18. 18.
    Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347–2353.CrossRefGoogle Scholar
  19. 19.
    Women’s health in rural China. Lancet 2009; 374: 358.Google Scholar
  20. 20.
    Li WJ, Xu HX, Chen ZH, Xu WD, Wu YJ. Characteristics of carcinogenic human papillomavirus infection in Suzhou: Epidemiology, vaccine evaluation, and associated diseases. J Med Virol 2017; 89: 895–901.CrossRefGoogle Scholar
  21. 21.
    Xu HH, Lin A, Chen YH, et al. Prevalence characteristics of cervical human papillomavirus (HPV) genotypes in the Taizhou area, China: a cross-sectional study of 37 967 women from the general population. BMJ Open 2017; 7: e014135.CrossRefGoogle Scholar
  22. 22.
    Liu X, Bi Y, Wang H, et al. Different Trends of Mortality from Colorectal Cancer between Age Groups in China: An Age-Period-Cohort and Joinpoint Analysis. Public Health 2018; 166: 45–52.Google Scholar
  23. 23.
    Wang L, Yu C, Liu Y, et al. Lung Cancer Mortality Trends in China from 1988 to 2013: New Challenges and Opportunities for the Government. Int J Environ Res Public Health 2016; 13: 1025.Google Scholar
  24. 24.
    Wang P, Xu C, Yu C. Age-period-cohort analysis on the cancer mortality in rural China: 1990-2010. Int J Equity Health 2014; 13: 1.CrossRefGoogle Scholar
  25. 25.
    Miao J, Wu X. Urbanization, socioeconomic status and health disparity in China. Health Place 2016; 42: 87–95.CrossRefGoogle Scholar
  26. 26.
    Li Z, Liu F, Cheng S, et al. Prevalence of HPV infection among 28,457 Chinese women in Yunnan Province, southwest China. Sci Rep 2016; 6: 21039.CrossRefGoogle Scholar
  27. 27.
    Shen Y, Gong JM, Li YQ, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China. Clin Chim Acta 2013; 415: 297–301.CrossRefGoogle Scholar
  28. 28.
    Wang R, Guo XL, Wisman GB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis 2015; 15: 257.CrossRefGoogle Scholar
  29. 29.
    Wu C, Zhu X, Kang Y, et al. Epidemiology of Humanpapilloma virus infection among women in Fujian, China. BMC Public Health 2017; 18: 95.CrossRefGoogle Scholar
  30. 30.
    Jing L, Zhong X, Zhong Z, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis 2014; 41: 732–738.CrossRefGoogle Scholar
  31. 31.
    Chen Z, Wang Q, Ding X, Li Q, Zhong R, Ren H. Characteristics of HPV prevalence in Sichuan Province, China. Int J Gynaecol Obstet 2015; 131: 277–280.CrossRefGoogle Scholar
  32. 32.
    Huang T, Liu Y, Li Y, et al. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5years of follow-up. Vaccine 2018; 36: 1368–1374.CrossRefGoogle Scholar
  33. 33.
    Zou H, Meng X, Jia T, et al. Awareness and acceptance of human papillomavirus (HPV) vaccination among males attending a major sexual health clinic in Wuxi, China: A cross-sectional study. Hum Vaccin Immunother 2016; 12: 1551–1559.CrossRefGoogle Scholar
  34. 34.
    Zou H, Wang W, Ma Y, et al. How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China. Hum Vaccin Immunother 2016; 12: 39–46.CrossRefGoogle Scholar
  35. 35.
    Wang Z, Wang J, Fang Y, et al. Parental acceptability of HPV vaccination for boys and girls aged 9-13years in China - A population-based study. Vaccine 2018; 36: 2657–2665.CrossRefGoogle Scholar
  36. 36.
    Wang B, He M, Chao A, et al. Cervical Cancer Screening Among Adult Women in China, 2010. Oncologist 2015; 20: 627–634.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2018

Authors and Affiliations

  • Min Wei
    • 1
    • 2
  • Wei Zhou
    • 2
  • Yongyi Bi
    • 2
  • Hong Wang
    • 2
  • Yu Liu
    • 3
  • Zhi-Jiang Zhang
    • 2
    Email author
  1. 1.Department of Obstetrics and GynecologyRenmin Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of Preventive Medicine, School of Health Sciences Wuhan UniversityWuhanChina
  3. 3.Department of Statistics and Management, School of ManagementWuhan Institute of TechnologyWuhanChina

Personalised recommendations